SCHEMBL5545185

SCHEMBL5545185

[CH2]CCCCC(=O)N1CCN(C(=O)OCc2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 4/20 0.46
HRH3 Q9Y5N1 6/20 0.46
ME2 P23368 1/20 0.45
ME1 P48163 1/20 0.45
ME3 Q16798 1/20 0.45
ATXN2 Q99700 3/20 0.44
PRKAB2 O43741 1/20 0.44
PRKAG1 P54619 1/20 0.44
PRKAA2 P54646 1/20 0.44
PRKAA1 Q13131 1/20 0.44
PRKAG3 Q9UGI9 1/20 0.44
PRKAG2 Q9UGJ0 1/20 0.44
PRKAB1 Q9Y478 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
CNR1 P21554 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 1/20 0.41
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538480 0.99 ENPP2 (0.45) ENPP2HRH3ME2ME1ME3
SCHEMBL5545275 0.96 HRH3 (0.46) ENPP2HRH3ME2ME1ME3
SCHEMBL5542452 0.92 HRH3 (0.48) ENPP2HRH3ME2ME1ME3
SCHEMBL27629714 0.88 HRH3 (0.51) ENPP2HRH3ME2ME1ME3
SCHEMBL5544923 0.88 HRH3 (0.48) HRH3ME2ME1ME3PRKAB2
SCHEMBL5543858 0.86 SIGMAR1 (0.46) ENPP2HRH3ATXN2L3MBTL1SMN1; SMN2
SCHEMBL5540479 0.85 SIGMAR1 (0.45) ENPP2HRH3ATXN2L3MBTL1SMN1; SMN2
SCHEMBL5544357 0.85 SIGMAR1 (0.47) ENPP2HRH3ATXN2L3MBTL1SMN1; SMN2
SCHEMBL5540430 0.83 L3MBTL1 (0.55) HRH3L3MBTL1SMN1; SMN2NPC1GAA
SCHEMBL5543639 0.82 ENPP2 (0.46) ENPP2HRH3ATXN2L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ENPP2 2915/4885HRH3 420/4885ME2 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.